VYNE Unblinds Early VYN202 Data After Safety Pause
VYNE Therapeutics updates on VYN202, revealing promising early results in psoriasis treatment despite a clinical hold due to safety concerns.
VYNE Therapeutics updates on VYN202, revealing promising early results in psoriasis treatment despite a clinical hold due to safety concerns.
Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.
This systematic review identifies patient-reported outcome measures that have been used in melanoma research and clinical practice and related melanoma-specific validation data.
We know that connecting with colleagues is essential. Meet new colleagues and catch up with everyone in your professional circle. Join us for the 2024…
At Elevate-Derm Summer, Jim Treat, MD, outlined diagnostic limitations of imaging and the importance of recognizing capillary malformation patterns linked to other diseases.
Johnson & Johnson seeks FDA approval to update guselkumab’s label, highlighting its unique ability to significantly inhibit joint damage in active psoriatic arthritis.
Lars French, MD, explains how the new WHA resolution on skin health could drive training, access, and global policy change.
Our current Author Spotlight features Natalia Neha Khosla MD MSc, who authored the article titled, “Socioeconomic Disparities in Gentle Skin Care Access for Atopic Dermatitis:…
By incorporating comorbidity surveillance into dermatologic care, clinicians can improve disease control, minimize therapeutic risks, and enhance overall patient quality of life.
This cohort study assesses the risk of new-onset and recurrent depression and anxiety among Danish patients with hidradenitis suppurativa from 1997 to 2022 and its…
Updated research finds that chronic stress disrupts healing processes and scar treatments, limiting the effectiveness of wound care in some patients.